{'fraction_non_alphanumeric': 0.03219178082191781, 'fraction_numerical': 0.03287671232876712, 'mean_word_length': 5.1645569620253164, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Selective dopamine D4 receptor agonist effects and their impact on regression of left ventricular hypertrophy in SH rats

Left ventricular hypertrophy is an adaptive response that involve a remodeling in heart tissues, however is associated with increased morbidity and mortality. In this study we characterized the effect of chronic administration of a selective dopamine D4 receptor agonist, the PD 168 099, in the left ventricular hypertrophy (LVH) in spontaneous hypertension rats (SHR). Male spontaneous hypertension rats (SHR), 2 months old, were distributed in 5 experimental groups, for daily drug oral administration during two months (metroprolol 100 mg/kg, losartan 50 mg/kg, bromocriptine 10 mg/kg, and PD 168 099 1 mg/Kg). After two months, systolic arterial blood pressure (SABP) by tail cut off occlusion method was recorder, after animals were sacrificed and hearts extracted, weighed and measured. In the sham groups, SABP, and ratio heart/body weight, were higher; 205±3 mmHg and 0.502±0.21, respectively. All drugs reduced the SABP, however the PD 168 099, was the most effective as losartan in decrease the ratio heart/body weight. Ours results demonstrate that PD 166 099 has a similar effect than losartan on the regression of left ventricular hypertrophy in the SH rats, suggesting that a selective dopamine D4 receptor agonist could be a good alternative as pharmacological treatment in LVH related to hypertension. Support from CONACYT